Department of Health Sciences, University of York, Heslington, York, UK.
Br Med Bull. 2010;96:5-21. doi: 10.1093/bmb/ldq033. Epub 2010 Oct 29.
The quality-adjusted life year (QALY) is routinely used as a summary measure of health outcome for economic evaluation, which incorporates the impact on both the quantity and quality of life. Key studies relating to the QALY and utility measurement are the sources of data. Areas of agreement include the need for a standard measure of health outcome to enable comparisons across different disease areas and populations, and the methods used for valuing health states in utility measurement. Areas of controversy include the limitation of the QALY approach in terms of the health benefits it can capture, its blindness towards equity concerns, the underlying theoretical assumptions and the most appropriate generic preference-based measure of utility. There is growing debate relating to whether a QALY is the same regardless of who accrues it, and also the issue as to who should value health states. Research is required to further enhance the QALY approach to deal with challenges relating to equity-weighted utility maximization and testing the validity of underlying assumptions. Issues around choosing between condition-specific measures and generic instruments also merit further investigation.
质量调整生命年(QALY)通常被用作经济评估的健康结果综合衡量指标,它综合考虑了生命数量和质量的影响。与 QALY 和效用测量相关的关键研究是数据的来源。达成共识的领域包括需要有一个标准的健康结果衡量指标,以便能够在不同的疾病领域和人群之间进行比较,以及在效用测量中用于衡量健康状况的方法。存在争议的领域包括 QALY 方法在其能够捕捉到的健康效益方面的局限性、对公平问题的盲目性、潜在的理论假设以及最适当的通用偏好基础效用衡量指标。关于 QALY 是否无论谁获得它都是相同的,以及谁应该评估健康状况的问题,存在越来越多的争论。需要进行研究以进一步增强 QALY 方法,以应对与公平加权效用最大化相关的挑战,并检验潜在假设的有效性。在选择特定于病情的衡量指标和通用工具之间的问题也值得进一步研究。